As mentioned previously, liraglutide, dulaglutide, albiglutide, and semaglutide have been shown to reduce the risk of cardiovascular events in patients with diabetes and either established ASCVD or high-risk characteristics in randomized controlled trials [35, 36, 49]
Research has characterised MT-IIs anorectic effects as MC4R-mediated through hypothalamic PVN and arcuate nucleus mechanisms , documenting food intake suppression kinetics, NPY/AgRP pathway suppression, and melanocortin pathway activation markers in hypothalamic tissue following MT-II treatment
Semaglutide, being a synthetic analog of GLP-1, shares a very similar chemical structure, allowing it to bind to and activate the same GLP-1 receptors in the body, but with a longer-lasting effect
This gives it great potential to help in the treatment and prevention of heart disease and heart failure 30 , specifically when combined with other treatments and lifestyle changes